| 发明名称 |
Clusterin Antisense Therapy for Treatment of Cancer |
| 摘要 |
A method for providing antisense therapy which reduces the expression of clusterin to provide therapeutic benefits in the treatment of cancer comprising administering from 40 to 640 mg anti-clusterin antisense oligonucleotide to a patient in need of treatment for a cancer expressing clusterin is provided. The method may include administering chemotherapeutic agent or agents, radiotherapy, and/or hormone ablation therapy. The invention also encompasses pharmaceutical compositions formulated to provide a dosage of 40 to 640 mg, and use of antisense in formulating a medicament. |
| 申请公布号 |
US2016168577(A1) |
申请公布日期 |
2016.06.16 |
| 申请号 |
US201514932396 |
申请日期 |
2015.11.04 |
| 申请人 |
The University of British Columbia |
发明人 |
Gleave Martin E.;Cormack Scott D. |
| 分类号 |
C12N15/113;A61K31/711;A61K31/337;A61K31/7068;A61K33/24 |
主分类号 |
C12N15/113 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A method for providing antisense therapy which reduces the expression of clusterin to provide therapeutic benefits in the treatment of cancer comprising the step of administering from 40 to 640 mg anti-clusterin antisense oligonucleotide to a patient in need of treatment for a cancer expressing clusterin. |
| 地址 |
Vancouver CA |
